Company: CRNX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-029050
Chunk: 300

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 1B
Chunk 300
---
 and between Isabel Kalofonos and the Registrant

    X

    10.28#
     
    Sales Agreement, dated June 21, 2024, by and among Crinetics Pharmaceuticals, Inc., Leerink Partners LLC and Cantor Fitzgerald & Co.
     
    8-K

    6/21/2024

    1.1

    10.29#
     
    Registration Rights Agreement, dated February 27, 2024, by and among Crinetics Pharmaceuticals, Inc. and the persons party thereto.
     
    8-K

    3/1/2024

    10.2

    10.30† 
     
    License Agreement, dated as of February 25, 2022, by and between Sanwa Kagaku Kenkyusho Co., Ltd. and the Registrant
     
    10-Q

    5/12/2022

    10.2

    19
     
    Insider Trading Compliance Policy
     
    10-K

    2/28/2024

    19

    21.1
     
    List of Subsidiaries of the Registrant
     
    S-1

    6/22/2018

    21.1

    23.1
     
    Consent of BDO USA, P.C., independent registered public accounting firm

    X

    31.1
      
    Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

    X

    31.2
      
    Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

    X

    32.1*
      
    Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 

    X

    32.2*
      
    Certification of Principal Financial Officer Pursuant to 18